News

New Panels Now Available

MNG Laboratories is excited to announce the release of 3 new panels to our testing portfolio. Each panel includes single-exon resolution copy number analysis to ensure that we are providing you with the most clinically sensitive testing possible. We also understand that pathogenic variants in the mitochondrial DNA (mtDNA) can be associated with an array of clinical presentations and mtDNA analysis is often overlooked when ordering genetic testing. That is why we include mtDNA sequencing and deletion testing in our relevant next-generation sequencing panels at no additional charge. NGS428: Tuberous Sclerosis Panel (2 Genes) Tuberous sclerosis (TSC) is a rare genetic disease causing benign tumors to grow in the brain and other vital organs such as kidneys, eyes, lungs, ears, and heart. Symptoms may present as seizures, mental retardation, and skin abnormalities. Heterozygous pathogenic variants can be found in 75%-90% of individuals who meet the clinical diagnostic criteria for TSC. Of the patients that are diagnosed with TSC, 31% are found to have pathogenic variants in the TSC1 gene and 69% in the TSC2 gene. NGS429:  Familial Hemiplegic Migraine Panel (5 Genes + mtDNA)  Familial Hemiplegic Migraine (FHM) is a dominantly inherited form of migraine characterized by intense, throbbing pain in one area of the head, often preceded by aura and accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Most individuals diagnosed with FHM have an affected parent. FHM is often earlier in onset than typical migraine. Approximately 40%-50% of patients have cerebellar signs ranging from nystagmus to progressive mild ataxia. NGS430: Stroke Panel (29 Genes + mtDNA) Stroke has a significant impact on patients, families and our healthcare system. It is the third largest cause of death, causing an estimated 10% of all deaths worldwide. Although many risk factors exist and contribute to the incidence of stroke, genetics can account for up to 50% of an individual’s risk of developing a stroke in the future. We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.